Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276631 | 0.84 | CES2 (0.50) | CES2CES1SRCCYP2D6DPP4 | |
| SCHEMBL11212730 | 0.77 | CES2 (0.44) | CES2CES1SRCCYP2D6DPP4 | |
| SCHEMBL3381285 | 0.74 | TAAR1 (0.44) | CES2CES1SRCCYP2D6TSHR | |
| SCHEMBL6957921 | 0.74 | TSHR (0.52) | CES2CES1SRCCYP2D6DPP4 | |
| SCHEMBL6959142 | 0.74 | CES2 (0.42) | CES2CES1SRCCYP2D6DPP4 | |
| SCHEMBL41570 | 0.71 | CES2 (0.50) | CES2CES1SRCCYP2D6DPP4 | |
| SCHEMBL2050459 | 0.71 | — | — | |
| SCHEMBL7847252 | 0.70 | ADRA2A (0.54) | SRCCYP2D6DPP4F2LMNA | |
| SCHEMBL10541083 | 0.70 | TSHR (0.48) | CES2CES1SRCCYP2D6TSHR | |
| SCHEMBL1403051 | 0.70 | ADRA2A (0.54) | SRCCYP2D6DPP4F2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615660-B2 | Production process of alkoxy-titanium complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20080306293-A1 | Production Process of Alkoxy-Titanium Complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-12-11 | — | — | US | disclosed |
| EP-1845101-A1 | METHOD FOR PRODUCING ALKOXYTITANIUM COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306293-A1 | Production Process of Alkoxy-Titanium Complex | ABL1, H1-10, ALK | CES2 3184/4885CES1 3119/4885SRC 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.